Cardurion Pharmaceuticals reveals breakthrough results in heart failure treatment with PDE9 inhibitor

In a significant development for cardiovascular disease treatment, Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company, has presented positive results from its Phase 2 proof-of-concept clinical ... Read More